EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Exact Sciences's Enterprise Value is $13,295 Mil.
Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-177 Mil. Therefore, Exact Sciences's EV-to-EBIT for today is -74.92.
The historical rank and industry rank for Exact Sciences's EV-to-EBIT or its related term are showing as below:
EXAS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -84.72 Med: -21.35 Max: -1.58
Current: -74.92
During the past 13 years, the highest EV-to-EBIT of Exact Sciences was -1.58. The lowest was -84.72. And the median was -21.35.
EXAS's EV-to-EBIT is ranked worse than 100% of 109
companies
in the Medical Diagnostics & Research industry
Industry Median: 18.95
vs EXAS: -74.92
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Exact Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $15,194 Mil.
Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-177 Mil. Exact Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.17%.
Exact Sciences EV-to-EBIT Historical Data
The historical data trend for Exact Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Exact Sciences Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBIT
-35.92
-26.45
-17.92
-17.17
-85.69
Exact Sciences Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBIT
-17.17
-27.76
-45.12
-54.56
-85.69
Competitive Comparison
For the Diagnostics & Research subindustry, Exact Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences EV-to-EBIT Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Exact Sciences's EV-to-EBIT falls into.
Exact Sciences EV-to-EBIT Calculation
Exact Sciences's EV-to-EBIT for today is calculated as:
Exact Sciences's current Enterprise Value is $13,295 Mil.
Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-177 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences (NAS:EXAS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Exact Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was $15,194 Mil.
Exact Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-177 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Exact Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences (Exact Sciences) Business Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 